HR-lowering Efficacy and Respiratory Safety of Ivabradine in Patients With Obstructive Airway Disease

Heart Rate Lowering Efficacy and Respiratory Safety of Ivabradine in Patients With Obstructive Airway Disease

The purpose of this study is to investigate heart rate lowering efficacy and respiratory safety of ivabradine in patients with asthma and COPD.

In this double blind, placebo-controlled, crossover study, 20 asthmatics and 20 COPD patients received ivabradine 7,5 mg b.i.d. and placebo for 5 days in crossover manner. HR in ECG holter monitoring, peak expiratory flow rate (PEFR), symptoms, rescue medication consumption and AEs were evaluated in both periods of treatment.

Inclusion Criteria:

• documented diagnosis of asthma or COPD in accordance with guidelines
• stable condition, defined as a disease without exacerbation for at least 1 month prior to study enrolment
• mean HR in holter ECG recording of ≥ 60 bpm

Exclusion Criteria:

• disease exacerbation in previous month
• inability to understand instructions on study procedures